India gets first dengue vaccine QDENGA: Who can get the jab, how effective is it and what is the dosage? Explained
India's drug regulator granted marketing authorisation for QDENGA (TAK-003), the country's first approved dengue vaccine, for use in individuals aged 4 to 60 years.
The vaccine can be administered regardless of prior dengue exposure and does not require pre-vaccination serostatus testing, unlike an earlier internationally available dengue vaccine.
A domestic manufacturing partnership between the vaccine's originator and an Indian vaccine maker aims to expand local supply, with a target capacity of 50 million doses annually.
The approval followed a review process in which the Subject Expert Committee on Vaccines under India's drug regulator recommended granting import/marketing permission in March 2026, based partly on Indian clinical trial data.
QDENGA (TAK-003) — Chimeric Live-Attenuated Tetravalent Vaccine Design
Dengue is caused by four distinct virus serotypes (DENV-1 to DENV-4), all of which must be neutralised for a vaccine to be broadly protective — a serotype missed by a vaccine can, under certain conditions, worsen subsequent infection through antibody-dependent enhancement. QDENGA is a "tetravalent" vaccine built to address all four serotypes using a chimeric design.
Key Details
- QDENGA (TAK-003) uses a live, attenuated DENV-2 strain as a genetic "backbone," into which the surface (pre-membrane and envelope) genes of DENV-1, DENV-3 and DENV-4 are substituted to create three additional chimeric viruses — together eliciting immunity to all four serotypes.
- The World Health Organization's Strategic Advisory Group of Experts (SAGE) recommended TAK-003 in September 2023 for children aged 6–16 years in settings with high dengue transmission intensity, without requiring pre-vaccination screening.
- Clinical trials reported roughly 61% efficacy against virologically confirmed symptomatic dengue and about 84% efficacy against dengue-related hospitalisation.
- QDENGA has been approved in over 40 countries and distributed in tens of millions of doses globally since its first launch in 2022.
India's approval brings the country access to a vaccine platform specifically engineered to avoid the immune-enhancement risk that limited the usability of an earlier dengue vaccine — directly relevant to how UPSC tests vaccine biotechnology (live attenuated vs. chimeric vs. subunit platforms).
Comparison with Dengvaxia — Why Serostatus Matters in Dengue Vaccination
Dengvaxia (Sanofi), the first dengue vaccine ever licensed globally, illustrated the central biological hazard in dengue vaccination: administering it to persons never previously infected with dengue can increase the risk of severe disease on a subsequent natural infection, because of antibody-dependent enhancement. This restricted Dengvaxia's use to only the dengue-seropositive.
Key Details
- Regulatory guidance in markets where Dengvaxia is approved limits its use to individuals with laboratory-confirmed prior dengue infection, typically aged 9–45 years.
- QDENGA's chimeric DENV-2-backbone design was developed specifically to be safe and effective irrespective of prior dengue exposure, removing the need for pre-vaccination testing.
- This design difference is the key reason QDENGA, and not Dengvaxia, has been approved for broad use across the 4–60 age band in India.
The article's emphasis that QDENGA can be given "without pre-vaccination testing" is a direct, testable consequence of its chimeric vaccine design compared with the serostatus-restricted first-generation dengue vaccine.
Regulatory Pathway — CDSCO, DCGI and the Subject Expert Committee
Vaccines and new drugs in India are approved through the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), operating under the New Drugs and Clinical Trials Rules, 2019.
Key Details
- The Subject Expert Committee (SEC) on Vaccines, a technical body under CDSCO, reviews safety, immunogenicity and efficacy data (including India-specific clinical trial data) before recommending marketing or import permission to the DCGI.
- QDENGA's approval process included a Phase III trial conducted in India, and the SEC recommended granting import/marketing permission in March 2026, ahead of the formal DCGI authorisation.
- The New Drugs and Clinical Trials Rules, 2019 govern the ethics committee registration, clinical trial approval and new-drug definition (which explicitly includes vaccines and biologics) underpinning this process.
The QDENGA approval is a textbook run of this SEC-to-DCGI pathway — a technical committee recommendation followed, months later, by formal regulatory authorisation — a process UPSC frequently tests in the context of drug and vaccine regulation.
India's Dengue Burden and Vector-Control Framework
Dengue is a major public-health concern in India, transmitted by the Aedes aegypti mosquito, which breeds in stagnant water in urban and peri-urban settings. The National Centre for Vector Borne Diseases Control (NCVBDC), under the Ministry of Health and Family Welfare, coordinates India's dengue surveillance and prevention strategy.
Key Details
- Reported dengue cases in India have risen sharply over the past two decades; India accounts for a substantial share of the global dengue burden, with outbreaks intensifying during and after the monsoon.
- NCVBDC's strategy (formerly the National Vector Borne Disease Control Programme, NVBDCP) rests on integrated vector management — entomological surveillance, source reduction, larvicide use and adult-mosquito control — supported by a network of sentinel surveillance hospitals for laboratory-confirmed diagnosis.
- Public-health experts caution that vaccination is a complementary tool, not a replacement for vector control, since no dengue vaccine offers complete, lifelong protection against all exposure scenarios.
QDENGA's rollout will be layered onto this existing Aedes aegypti vector-control framework rather than replacing it — a "prevention-plus-vaccination" model relevant to Mains answers on India's communicable disease strategy.
- QDENGA (TAK-003) approved for ages 4–60 years in India; no pre-vaccination serostatus testing required.
- Vaccine design: live-attenuated, chimeric, DENV-2 genetic backbone carrying DENV-1/3/4 surface antigens; tetravalent (covers all four dengue serotypes).
- Reported efficacy: ~61% against symptomatic dengue; ~84% against dengue-related hospitalisation.
- WHO SAGE recommendation: September 2023, for ages 6–16 in high-transmission settings.
- India regulatory approval process: CDSCO Subject Expert Committee on Vaccines recommendation, March 2026, under DCGI/New Drugs and Clinical Trials Rules, 2019.
- Domestic manufacturing target: 50 million doses annually via an Indian vaccine-manufacturing partner.
- Primary dengue vector in India: Aedes aegypti; nodal agency: National Centre for Vector Borne Diseases Control (NCVBDC), Ministry of Health and Family Welfare.